atc_level_01_code,atc_level_01_name,atc_level_02_code,atc_level_02_name,atc_level_03_code,atc_level_03_name,atc_level_04_code,atc_level_04_name,atc_level_04_note,atc_level_05_code,atc_level_05_name,atc_level_05_note,DDD_O,DDD_oral_aerosol,DDD_P,DDD_R,DDD_SL,DDD_TD,unit_O,unit_oral_aerosol,unit_P,unit_R,unit_SL,unit_TD
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA01,acetyldigitoxin,NA,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA02,acetyldigoxin,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA03,digitalis leaves,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA04,digitoxin,NA,0.1,NA,0.1,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA05,digoxin,NA,0.25,NA,0.25,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA06,lanatoside C,NA,1,NA,NA,1,NA,NA,mg,NA,NA,mg,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA07,deslanoside,Acute treatment,NA,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA08,metildigoxin,NA,0.2,NA,0.2,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA09,gitoformate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA52,"acetyldigoxin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AB,Scilla glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AB01,proscillaridin,NA,0.75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AB,Scilla glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AB51,"proscillaridin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AC,Strophanthus glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AC01,g-strophanthin,NA,NA,NA,0.25,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AC,Strophanthus glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AC03,cymarin,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AX,Other cardiac glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AX02,peruvoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA01,quinidine,NA,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA02,procainamide,NA,3,NA,3,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA03,disopyramide,NA,0.4,NA,0.4,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA04,sparteine,NA,NA,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA05,ajmaline,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA08,prajmaline,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA12,lorajmine,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA13,hydroquinidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA51,"quinidine, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA71,"quinidine, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB01,lidocaine,NA,NA,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB02,mexiletine,NA,0.8,NA,0.8,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB03,tocainide,NA,1.2,NA,1.2,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB04,aprindine,NA,0.1,NA,0.1,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC03,propafenone,NA,0.3,NA,0.3,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC04,flecainide,NA,0.2,NA,0.2,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC07,lorcainide,NA,NA,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC08,encainide,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC09,ethacizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD01,amiodarone,NA,0.2,NA,0.2,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD02,bretylium tosilate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD03,bunaftine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD04,dofetilide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD05,ibutilide,NA,NA,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD06,tedisamil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD07,dronedarone,NA,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BG,"Other antiarrhythmics, class I and III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BG01,moracizine,NA,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BG,"Other antiarrhythmics, class I and III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BG07,cibenzoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BG,"Other antiarrhythmics, class I and III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BG11,vernakalant,NA,NA,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA01,etilefrine,NA,50,NA,50,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA02,isoprenaline,NA,90,NA,90,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA03,norepinephrine,NA,NA,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA04,dopamine,NA,NA,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA05,norfenefrine,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA06,phenylephrine,NA,NA,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA07,dobutamine,NA,NA,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA08,oxedrine,NA,0.2,NA,0.2,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA09,metaraminol,NA,NA,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA10,methoxamine,NA,NA,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA11,mephentermine,NA,NA,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA12,dimetofrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA13,prenalterol,NA,NA,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA14,dopexamine,NA,NA,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA15,gepefrine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA16,ibopamine,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA17,midodrine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA18,octopamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA19,fenoldopam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA21,cafedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA22,arbutamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA23,theodrenaline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA24,epinephrine,NA,NA,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA25,amezinium metilsulfate,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA26,ephedrine,NA,NA,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA27,droxidopa,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA28,centhaquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA51,"etilefrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE01,amrinone,NA,NA,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE02,milrinone,NA,NA,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE03,enoximone,NA,NA,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE04,bucladesine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX06,angiotensinamide,NA,NA,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX07,xamoterol,NA,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX08,levosimendan,NA,NA,NA,11,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX09,angiotensin II,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX10,omecamtiv mecarbil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA02,glyceryl trinitrate,NA,5,2.5,NA,NA,2.5,5,mg,mg,NA,NA,mg,mg
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA04,methylpropylpropanediol dinitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA05,pentaerithrityl tetranitrate,NA,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA07,propatylnitrate,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA08,isosorbide dinitrate,NA,60,20,NA,NA,20,0.1,mg,mg,NA,NA,mg,g
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA09,trolnitrate,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA13,eritrityl tetranitrate,NA,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA14,isosorbide mononitrate,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA20,organic nitrates in combination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA38,tenitramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA52,"glyceryl trinitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA54,"methylpropylpropanediol dinitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA55,"pentaerithrityl tetranitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA57,"propatylnitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA58,"isosorbide dinitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA59,"trolnitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA63,"eritrityl tetranitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA70,organic nitrates in combination with psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DB,Quinolone vasodilators,NA,C01DB01,flosequinan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX01,itramin tosilate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX02,prenylamine,NA,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX03,oxyfedrine,NA,40,NA,40,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX04,benziodarone,NA,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX05,carbocromen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX06,hexobendine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX07,etafenone,NA,0.225,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX08,heptaminol,NA,0.45,NA,0.45,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX09,imolamine,NA,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX10,dilazep,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX11,trapidil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX12,molsidomine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX13,efloxate,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX14,cinepazet,NA,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX15,cloridarol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX16,nicorandil,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX18,linsidomine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX19,nesiritide,NA,NA,NA,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX21,serelaxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX22,vericiguat,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX51,"itramin tosilate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX52,"prenylamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX53,"oxyfedrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX54,"benziodarone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EA,Prostaglandins,The DDD for alprostadil equals the content of active substance in one ampoule.,C01EA01,alprostadil,NA,NA,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB02,camphora,NA,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB03,indometacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB04,crataegus glycosides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB05,creatinolfosfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB06,fosfocreatine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB07,"fructose 1,6-diphosphate",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB09,ubidecarenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB10,adenosine,NA,NA,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB11,tiracizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB13,acadesine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB15,trimetazidine,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB16,ibuprofen,NA,NA,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB17,ivabradine,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB18,ranolazine,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB21,regadenoson,NA,NA,NA,0.4,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB22,meldonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB23,tiazotic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB24,mavacamten,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EX,Other cardiac combination products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA01,rescinnamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA02,reserpine,NA,0.5,NA,0.5,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA03,combinations of rauwolfia alkaloids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA04,"rauwolfia alkaloids, whole root",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA05,deserpidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA06,methoserpidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA07,bietaserpine,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA52,"reserpine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA53,"combinations of rauwolfia alkoloids, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA57,"bietaserpine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AB,Methyldopa,"The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). Different DDDs have been established for the various stereoiso-meric forms of methyldopa, because of different potency.",C02AB01,methyldopa (levorotatory),NA,1,NA,1,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AB,Methyldopa,"The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). Different DDDs have been established for the various stereoiso-meric forms of methyldopa, because of different potency.",C02AB02,methyldopa (racemic),NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC01,clonidine,NA,0.45,NA,0.45,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC02,guanfacine,NA,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC04,tolonidine,NA,0.75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC05,moxonidine,NA,0.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC06,rilmenidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02B,"ANTIADRENERGIC AGENTS, GANGLION-BLOCKING",C02BA,Sulfonium derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02BA01,trimetaphan,NA,NA,NA,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02B,"ANTIADRENERGIC AGENTS, GANGLION-BLOCKING",C02BB,Secondary and tertiary amines,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02BB01,mecamylamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02B,"ANTIADRENERGIC AGENTS, GANGLION-BLOCKING",C02BC,Bisquaternary ammonium compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA01,prazosin,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA02,indoramin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA03,trimazosin,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA04,doxazosin,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA06,urapidil,NA,0.12,NA,50,NA,NA,NA,g,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC01,betanidine,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC02,guanethidine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC03,guanoxan,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC04,debrisoquine,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC05,guanoclor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC06,guanazodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC07,guanoxabenz,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DA,Thiazide derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DA01,diazoxide,NA,NA,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB01,dihydralazine,NA,75,NA,25,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB02,hydralazine,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB03,endralazine,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB04,cadralazine,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DC,Pyrimidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DC01,minoxidil,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DD,Nitroferricyanide derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DD01,nitroprusside,NA,NA,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DG,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DG01,pinacidil,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KA,"Alkaloids, excl. rauwolfia",The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KA01,veratrum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KB,Tyrosine hydroxylase inhibitors,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KB01,metirosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KC,MAO inhibitors,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KC01,pargyline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KD,Serotonin antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KD01,ketanserin,NA,40,NA,40,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KN,Other antihypertensives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KN01,aprocitentan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX01,bosentan,NA,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX02,ambrisentan,NA,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX03,sitaxentan,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX04,macitentan,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX05,riociguat,NA,4.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX52,ambrisentan and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX54,macitentan and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA01,reserpine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA02,rescinnamine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA03,deserpidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA04,methoserpidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA07,bietaserpine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA08,"rauwolfia alkaloids, whole root and diuretics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA09,syrosingopine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA50,combination of rauwolfia alkaloids and diuretics incl. other combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA51,"reserpine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA52,"rescinnamine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA71,"reserpine and diuretics, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LB,Methyldopa and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LB01,methyldopa (levorotatory) and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LC,Imidazoline receptor agonists in combination with diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LC01,clonidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LC,Imidazoline receptor agonists in combination with diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LC05,moxonidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LC,Imidazoline receptor agonists in combination with diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LC51,"clonidine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LE,Alpha-adrenoreceptor antagonists and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LE01,prazosin and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LF,Guanidine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LF01,guanethidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG01,dihydralazine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG02,hydralazine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG03,picodralazine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG51,"dihydralazine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG73,"picodralazine and diuretics, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LK,"Alkaloids, excl. rauwolfia, in combination with diuretics",The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LK01,veratrum and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LL,MAO inhibitors and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LL01,pargyline and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LN,Serotonin antagonists and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LX,Other antihypertensives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LX01,pinacidil and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02N,COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA01,bendroflumethiazide,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA02,hydroflumethiazide,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA03,hydrochlorothiazide,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA04,chlorothiazide,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA05,polythiazide,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA06,trichlormethiazide,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA07,cyclopenthiazide,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA08,methyclothiazide,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA09,cyclothiazide,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA13,mebutizide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB01,bendroflumethiazide and potassium,Refers to bendroflumethiazide,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB02,hydroflumethiazide and potassium,Refers to hydroflumethiazide,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB03,hydrochlorothiazide and potassium,Refers to hydrochlorothiazide,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB04,chlorothiazide and potassium,Refers to chlorothiazide,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB05,polythiazide and potassium,Refers to polythiazide,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB06,trichlormethiazide and potassium,Refers to trichlormethiazide,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB07,cyclopenthiazide and potassium,Refers to cyclopenthiazide,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB08,methyclothiazide and potassium,Refers to methyclothiazide,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB09,cyclothiazide and potassium,Refers to cyclothiazide,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AH,"Thiazides, combinations with psycholeptics and/or analgesics","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AH01,"chlorothiazide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AH,"Thiazides, combinations with psycholeptics and/or analgesics","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AH02,"hydroflumethiazide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AX,"Thiazides, combinations with other drugs","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AX01,"hydrochlorothiazide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA02,quinethazone,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA03,clopamide,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA04,chlortalidone,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA05,mefruside,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA07,clofenamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA08,metolazone,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA09,meticrane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA10,xipamide,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA11,indapamide,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA12,clorexolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA13,fenquizone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA82,"clorexolone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB02,quinethazone and potassium,Refers to quinethazone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB03,clopamide and potassium,Refers to clopamide,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB04,chlortalidone and potassium,Refers to chlortalidone,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB05,mefruside and potassium,Refers to mefruside,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB07,clofenamide and potassium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BC,Mercurial diuretics,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BC01,mersalyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BD,Xanthine derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BD01,theobromine,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BK,"Sulfonamides, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BX,Other low-ceiling diuretics,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BX03,cicletanine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA01,furosemide,NA,40,NA,40,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA02,bumetanide,NA,1,NA,1,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA03,piretanide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA04,torasemide,NA,15,NA,15,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CB01,furosemide and potassium,Refers to furosemide,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CB02,bumetanide and potassium,Refers to bumetanide,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CC,Aryloxyacetic acid derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CC01,etacrynic acid,NA,50,NA,50,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CC,Aryloxyacetic acid derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CC02,tienilic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CD,Pyrazolone derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CD01,muzolimine,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CX,Other high-ceiling diuretics,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CX01,etozolin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA01,spironolactone,NA,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA02,potassium canrenoate,NA,NA,NA,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA03,canrenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA04,eplerenone,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA05,finerenone,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DB,Other potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03DB01,amiloride,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DB,Other potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03DB02,triamterene,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA01,hydrochlorothiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA02,trichlormethiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA03,epitizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA04,altizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA05,mebutizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA06,chlortalidone and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA07,cyclopenthiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA12,metolazone and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA13,bendroflumethiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA14,butizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EB,High-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EB01,furosemide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EB,High-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EB02,bumetanide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03X,OTHER DIURETICS,C03XA,Vasopressin antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03XA01,tolvaptan,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03X,OTHER DIURETICS,C03XA,Vasopressin antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03XA02,conivaptan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AA,2-amino-1-phenylethanol derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AA01,isoxsuprine,NA,60,NA,60,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AA,2-amino-1-phenylethanol derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AA02,buphenine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AA,2-amino-1-phenylethanol derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AA31,bamethan,NA,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AB,Imidazoline derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AB01,phentolamine,NA,10,NA,10,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AB,Imidazoline derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AB02,tolazoline,NA,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC01,nicotinic acid,NA,0.2,NA,0.2,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC02,nicotinyl alcohol (pyridylcarbinol),NA,0.3,NA,0.3,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC03,inositol nicotinate,NA,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC07,ciclonicate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD01,pentifylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD02,xantinol nicotinate,NA,0.9,NA,0.9,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD03,pentoxifylline,NA,1,NA,0.3,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD04,etofylline nicotinate,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE01,ergoloid mesylates,NA,3,NA,3,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE02,nicergoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE04,dihydroergocristine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE51,"ergoloid mesylates, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE54,"dihydroergocristine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AF,Enzymes,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AF01,kallidinogenase,NA,30,NA,30,NA,NA,NA,U,NA,U,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX01,cyclandelate,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX02,phenoxybenzamine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX07,vincamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX10,moxisylyte,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX11,bencyclane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX17,vinburnine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX19,suloctidil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX20,buflomedil,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX21,naftidrofuryl,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX23,butalamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX24,visnadine,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX26,cetiedil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX27,cinepazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX28,ifenprodil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX30,azapetine,NA,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX32,fasudil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX33,clazosentan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA01,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA04,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA05,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA06,fluorometholone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA08,fluocortolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA09,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA10,fluocinolone acetonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA11,fluocinonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA12,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AB,Antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD01,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD02,tetracaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD03,benzocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD04,cinchocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD05,procaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD06,oxetacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD07,pramocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AE,Muscle relaxants,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AE01,glyceryl trinitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AE,Muscle relaxants,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AE02,isosorbide dinitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AE,Muscle relaxants,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AE03,diltiazem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX01,aluminium preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX02,"bismuth preparations, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX03,"other preparations, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX04,zinc preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX05,tribenoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX06,phenylephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA01,organo-heparinoid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA02,sodium apolate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA03,heparin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA04,pentosan polysulfate sodium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA51,"heparinoid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA53,"heparin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB01,monoethanolamine oleate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB02,polidocanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB03,invert sugar,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB04,sodium tetradecyl sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB05,phenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB56,"glucose, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BX,Other sclerosing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BX01,calcium dobesilate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BX,Other sclerosing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BX51,"calcium dobesilate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA01,rutoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA02,monoxerutin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA03,diosmin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA04,troxerutin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA05,hidrosmin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA51,"rutoside, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA53,"diosmin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA54,"troxerutin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CX,Other capillary stabilizing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CX01,tribenoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CX,Other capillary stabilizing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CX02,naftazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CX,Other capillary stabilizing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CX03,Hippocastani semen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05X,OTHER VASOPROTECTIVES,C05XX,Other vasoprotectives,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05XX01,beperminogene perplasmid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA01,alprenolol,NA,0.4,NA,0.4,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA02,oxprenolol,NA,0.16,NA,0.16,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA03,pindolol,NA,15,NA,15,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA05,propranolol,NA,0.16,NA,0.16,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA06,timolol,NA,20,NA,20,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA07,sotalol,NA,0.16,NA,0.16,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA12,nadolol,NA,0.16,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA14,mepindolol,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA15,carteolol,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA16,tertatolol,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA17,bopindolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA19,bupranolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA23,penbutolol,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA27,cloranolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB01,practolol,NA,0.3,NA,20,NA,NA,NA,g,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB02,metoprolol,NA,0.15,NA,0.15,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB03,atenolol,NA,75,NA,75,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB04,acebutolol,NA,0.4,NA,0.4,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB05,betaxolol,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB06,bevantolol,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB07,bisoprolol,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB08,celiprolol,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB09,esmolol,NA,NA,NA,2.5,NA,NA,NA,NA,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB10,epanolol,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB11,s-atenolol,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB12,nebivolol,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB13,talinolol,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB14,landiolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AG,Alpha and beta blocking agents,"The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AG01,labetalol,NA,0.6,NA,0.6,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AG,Alpha and beta blocking agents,"The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AG02,carvedilol,NA,37.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA02,oxprenolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA05,propranolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA06,timolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA07,sotalol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA12,nadolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA68,"metipranolol and thiazides, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB02,metoprolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB03,atenolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB04,acebutolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB06,bevantolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB07,bisoprolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB12,nebivolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB52,"metoprolol and thiazides, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BG,Alpha and beta blocking agents and thiazides,See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BG01,labetalol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA02,oxprenolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA03,pindolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA17,bopindolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA23,penbutolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CB,"Beta blocking agents, selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CB02,metoprolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CB,"Beta blocking agents, selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CB03,atenolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CB,"Beta blocking agents, selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CB53,"atenolol and other diuretics, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CG,Alpha and beta blocking agents and other diuretics,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CG01,labetalol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07D,"BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS",C07DA,"Beta blocking agents, non-selective, thiazides and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07DA06,"timolol, thiazides and other diuretics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07D,"BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS",C07DB,"Beta blocking agents, selective, thiazides and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07DB01,"atenolol, thiazides and other diuretics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07E,BETA BLOCKING AGENTS AND VASODILATORS,C07EA,"Beta blocking agents, non-selective, and vasodilators",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07E,BETA BLOCKING AGENTS AND VASODILATORS,C07EB,"Beta blocking agents, selective, and vasodilators",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB02,metoprolol and felodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB03,atenolol and nifedipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB07,bisoprolol and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB12,nebivolol and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB13,metoprolol and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX01,propranolol and other combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX02,sotalol and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX03,metoprolol and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX04,bisoprolol and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX05,metoprolol and ivabradine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX06,carvedilol and ivabradine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA01,amlodipine,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA02,felodipine,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA03,isradipine,NA,5,NA,5,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA04,nicardipine,NA,90,NA,90,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA05,nifedipine,NA,30,NA,30,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA06,nimodipine,NA,0.3,NA,50,NA,NA,NA,g,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA07,nisoldipine,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA08,nitrendipine,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA09,lacidipine,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA10,nilvadipine,NA,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA11,manidipine,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA12,barnidipine,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA13,lercanidipine,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA14,cilnidipine,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA15,benidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA16,clevidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA17,levamlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA51,amlodipine and celecoxib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA55,"nifedipine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CX,Other selective calcium channel blockers with mainly vascular effects,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CX01,mibefradil,NA,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DA01,verapamil,NA,0.24,NA,0.24,NA,NA,NA,g,NA,g,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DA02,gallopamil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DA51,"verapamil, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DB,Benzothiazepine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DB01,diltiazem,NA,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EA01,fendiline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EA02,bepridil,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EX,Other non-selective calcium channel blockers,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EX01,lidoflazine,NA,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EX,Other non-selective calcium channel blockers,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EX02,perhexiline,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08G,CALCIUM CHANNEL BLOCKERS AND DIURETICS,C08GA,Calcium channel blockers and diuretics,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08GA01,nifedipine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08G,CALCIUM CHANNEL BLOCKERS AND DIURETICS,C08GA,Calcium channel blockers and diuretics,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08GA02,amlodipine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA01,captopril,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA02,enalapril,NA,10,NA,10,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA03,lisinopril,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA04,perindopril,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA05,ramipril,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA06,quinapril,NA,15,NA,15,NA,NA,NA,mg,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA07,benazepril,NA,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA08,cilazapril,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA09,fosinopril,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA10,trandolapril,NA,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA11,spirapril,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA12,delapril,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA13,moexipril,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA14,temocapril,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA15,zofenopril,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA16,imidapril,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA01,captopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA02,enalapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA03,lisinopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA04,perindopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA05,ramipril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA06,quinapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA07,benazepril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA08,cilazapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA09,fosinopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA12,delapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA13,moexipril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA15,zofenopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB02,enalapril and lercanidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB03,lisinopril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB04,perindopril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB05,ramipril and felodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB06,enalapril and nitrendipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB07,ramipril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB10,trandolapril and verapamil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB12,delapril and manidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB13,benazepril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX01,"perindopril, amlodipine and indapamide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX02,perindopril and bisoprolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX03,"ramipril, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX04,"perindopril, bisoprolol and amlodipine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX05,ramipril and bisoprolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX06,"perindopril, bisoprolol, amlodipine and indapamide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX07,zofenopril and nebivolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA01,losartan,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA02,eprosartan,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA03,valsartan,NA,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA04,irbesartan,NA,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA05,tasosartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA06,candesartan,NA,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA07,telmisartan,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA08,olmesartan medoxomil,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA09,azilsartan medoxomil,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA10,fimasartan,NA,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA01,losartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA02,eprosartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA03,valsartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA04,irbesartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA06,candesartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA07,telmisartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA08,olmesartan medoxomil and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA09,azilsartan medoxomil and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA10,fimasartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB01,valsartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB02,olmesartan medoxomil and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB04,telmisartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB05,irbesartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB06,losartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB07,candesartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB08,valsartan and lercanidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB09,fimasartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX01,"valsartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX02,valsartan and aliskiren,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX03,"olmesartan medoxomil, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX04,valsartan and sacubitril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX05,valsartan and nebivolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX06,"candesartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX07,"irbesartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX08,"telmisartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA01,remikiren,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA02,aliskiren,NA,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA52,aliskiren and hydrochlorothiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA53,aliskiren and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA54,"aliskiren, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA01,simvastatin,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA02,lovastatin,NA,45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA03,pravastatin,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA04,fluvastatin,NA,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA05,atorvastatin,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA06,cerivastatin,NA,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA07,rosuvastatin,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA08,pitavastatin,NA,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB01,clofibrate,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB02,bezafibrate,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB03,aluminium clofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB04,gemfibrozil,NA,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB05,fenofibrate,micronised,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB06,simfibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB07,ronifibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB08,ciprofibrate,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB09,etofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB10,clofibride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB11,choline fenofibrate,Refers to fenofibric acid,0.135,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB12,pemafibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC01,colestyramine,NA,14,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC02,colestipol,NA,20,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC03,colextran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC04,colesevelam,NA,3.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD01,niceritrol,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD02,nicotinic acid,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD03,nicofuranose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD04,aluminium nicotinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD05,nicotinyl alcohol (pyridylcarbinol),NA,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD06,acipimox,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD52,"nicotinic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX01,dextrothyroxine,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX02,probucol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX03,tiadenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX05,meglutol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX06,omega-3-triglycerides incl. other esters and acids,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX07,magnesium pyridoxal 5-phosphate glutamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX08,policosanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX09,ezetimibe,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX10,alipogene tiparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX11,mipomersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX12,lomitapide,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX13,evolocumab,NA,NA,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX14,alirocumab,NA,NA,NA,5.4,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX15,bempedoic acid,NA,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX16,inclisiran,NA,NA,NA,1.6,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX17,evinacumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX18,volanesorsen,NA,NA,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA01,lovastatin and nicotinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA02,simvastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA03,pravastatin and fenofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA04,simvastatin and fenofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA05,atorvastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA06,rosuvastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA07,rosuvastatin and omega-3 fatty acids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA08,atorvastatin and omega-3 fatty acids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA09,rosuvastatin and fenofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA10,bempedoic acid and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA11,pravastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA12,"pravastatin, ezetimibe and fenofibrate",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX01,simvastatin and acetylsalicylic acid,Refers to simvastatin,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX02,pravastatin and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX03,atorvastatin and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX04,"simvastatin, acetylsalicylic acid and ramipril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX05,rosuvastatin and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX06,"atorvastatin, acetylsalicylic acid and ramipril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX07,"rosuvastatin, amlodipine and lisinopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX08,atorvastatin and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX09,rosuvastatin and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX10,rosuvastatin and valsartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX11,"atorvastatin, amlodipine and perindopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX12,"atorvastatin, acetylsalicylic acid and perindopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX13,"rosuvastatin, perindopril and indapamide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX14,"rosuvastatin, amlodipine and perindopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX15,atorvastatin and perindopril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX16,rosuvastatin and fimasartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX17,rosuvastatin and ramipril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX18,"atorvastatin, amlodipine and ramipril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX19,"atorvastatin, amlodipine and candesartan",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX20,rosuvastatin and telmisartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX21,rosuvastatin and perindopril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
